DERM Quote, Financials, Valuation and Earnings

Fortress Biotech, Inc. has a net margin of -13.13% compared to Journey Medical Corp.'s net margin of 50.07%. Journey Medical Corp.'s return on equity of -44.34% beat Fortress Biotech, Inc.'s return on equity of -223.06%.

Journey Medical Corp. has a consensus price target of $13.50, signalling upside risk potential of 62.07%. On the other hand Fortress Biotech, Inc. has an analysts' consensus of $10.75 which suggests that it could grow by 218.05%. Given that Fortress Biotech, Inc. has higher upside potential than Journey Medical Corp., analysts believe Fortress Biotech, Inc. is more attractive than Journey Medical Corp..

Journey Medical Corp. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Fortress Biotech, Inc. has a beta of 1.423, suggesting its more volatile than the S&P 500 by 42.327%.

Journey Medical Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Fortress Biotech, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Journey Medical Corp. pays -- of its earnings as a dividend. Fortress Biotech, Inc. pays out 3.9% of its earnings as a dividend. Fortress Biotech, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Journey Medical Corp. quarterly revenues are $17.6M, which are smaller than Fortress Biotech, Inc. quarterly revenues of $17.6M. Journey Medical Corp.'s net income of -$2.3M is lower than Fortress Biotech, Inc.'s net income of $8.8M. Notably, Journey Medical Corp.'s price-to-earnings ratio is -- while Fortress Biotech, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Journey Medical Corp. is 3.26x versus 1.59x for Fortress Biotech, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals, Inc. has a net margin of -13.13% compared to Journey Medical Corp.'s net margin of -255.85%. Journey Medical Corp.'s return on equity of -44.34% beat NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03%.

Journey Medical Corp. has a consensus price target of $13.50, signalling upside risk potential of 62.07%. On the other hand NovaBay Pharmaceuticals, Inc. has an analysts' consensus of $0.85 which suggests that it could fall by -57.5%. Given that Journey Medical Corp. has higher upside potential than NovaBay Pharmaceuticals, Inc., analysts believe Journey Medical Corp. is more attractive than NovaBay Pharmaceuticals, Inc..

Journey Medical Corp. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals, Inc. has a beta of 0.093, suggesting its less volatile than the S&P 500 by 90.725%.

Journey Medical Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.80 per share. Journey Medical Corp. pays -- of its earnings as a dividend. NovaBay Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Journey Medical Corp. quarterly revenues are $17.6M, which are larger than NovaBay Pharmaceuticals, Inc. quarterly revenues of $521K. Journey Medical Corp.'s net income of -$2.3M is lower than NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M. Notably, Journey Medical Corp.'s price-to-earnings ratio is -- while NovaBay Pharmaceuticals, Inc.'s PE ratio is 3.36x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Journey Medical Corp. is 3.26x versus 3.89x for NovaBay Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Palatin Technologies has a net margin of -13.13% compared to Journey Medical Corp.'s net margin of --. Journey Medical Corp.'s return on equity of -44.34% beat Palatin Technologies's return on equity of --.

Journey Medical Corp. has a consensus price target of $13.50, signalling upside risk potential of 62.07%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 7338.9%. Given that Palatin Technologies has higher upside potential than Journey Medical Corp., analysts believe Palatin Technologies is more attractive than Journey Medical Corp..

Journey Medical Corp. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.939, suggesting its less volatile than the S&P 500 by 6.103%.

Journey Medical Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Journey Medical Corp. pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

Journey Medical Corp. quarterly revenues are $17.6M, which are larger than Palatin Technologies quarterly revenues of --. Journey Medical Corp.'s net income of -$2.3M is higher than Palatin Technologies's net income of --. Notably, Journey Medical Corp.'s price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Journey Medical Corp. is 3.26x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Theriva Biologics, Inc. has a net margin of -13.13% compared to Journey Medical Corp.'s net margin of --. Journey Medical Corp.'s return on equity of -44.34% beat Theriva Biologics, Inc.'s return on equity of -171.04%.

Journey Medical Corp. has a consensus price target of $13.50, signalling upside risk potential of 62.07%. On the other hand Theriva Biologics, Inc. has an analysts' consensus of $7.00 which suggests that it could grow by 3563%. Given that Theriva Biologics, Inc. has higher upside potential than Journey Medical Corp., analysts believe Theriva Biologics, Inc. is more attractive than Journey Medical Corp..

Journey Medical Corp. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Theriva Biologics, Inc. has a beta of 0.343, suggesting its less volatile than the S&P 500 by 65.729%.

Journey Medical Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Journey Medical Corp. pays -- of its earnings as a dividend. Theriva Biologics, Inc. pays out -- of its earnings as a dividend.

Journey Medical Corp. quarterly revenues are $17.6M, which are larger than Theriva Biologics, Inc. quarterly revenues of --. Journey Medical Corp.'s net income of -$2.3M is higher than Theriva Biologics, Inc.'s net income of -$4.4M. Notably, Journey Medical Corp.'s price-to-earnings ratio is -- while Theriva Biologics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Journey Medical Corp. is 3.26x versus 0.33x for Theriva Biologics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.